• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lupus >The multi-targets mechanism of hydroxychloroquine in the treatment of systemic lupus erythematosus based on network pharmacology
【24h】

The multi-targets mechanism of hydroxychloroquine in the treatment of systemic lupus erythematosus based on network pharmacology

机译：基于网络药理学的羟基氯喹的多目标机制

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Network pharmacology is used with bioinformatic tools to broaden the understanding of drugs' potential targets and the intersections with key genes of particular disease. Here we applied network pharmacology to collect testable hypotheses about the multi-targets mechanism of hydroxychloroquine (HCQ) against systemic lupus erythematosus (SLE). Methods Firstly, we predicted the potential targets of HCQ. Secondly, we got the related genes of SLE returned from databases. Thirdly, the intersections of the potential targets (HCQ) and related genes (SLE) were analyzed with gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment. Finally, we validated our predictions of the potential targets by performing docking studies with HCQ. Results The results suggest that the efficacy of HCQ against SLE is mainly associated with the targets of cyclin-dependent kinase 2 (CDK2), estrogen receptor alpha (ESR1) and CDK1, which regulate PI3K/Akt/GSK3 beta as well as interferon (IFN) signaling pathway. Biological process of the network associated with the three targets is concentrated in the inhibition of immune response, negative regulation of gene expression and regulation of immune system process. Molecular docking analysis proves that hydrogen bonding and pi-pi stacking are the main forms of interaction. Conclusions Our research provides protein targets affected by HCQ in the treatment of SLE. Three key targets (CDK2, ESR1 and CDK1) involving 1766 proteins become the multi-targets mechanism of HCQ in the treatment of SLE. As well, the research also provides a new idea for introducing network pharmacology into the evaluation of the drugs with multi-targets in dermatology.
机译：None

著录项

  • 来源
    《Lupus》 |2020年第13期|共8页
  • 作者

    Xie Bo; Geng Qingwei; Xu Jinhui; Lu Haojie; Luo Haixin; Hu Yebei; Song Xiuzu;

  • 作者单位

    Zhejiang Chinese Med Univ Hangzhou Peoples Hosp 3 Dept Dermatol West Lake Rd 38 Hangzhou 310009;

    Zhejiang Chinese Med Univ Hangzhou Peoples Hosp 3 Dept Dermatol West Lake Rd 38 Hangzhou 310009;

    Zhejiang Chinese Med Univ Hangzhou Peoples Hosp 3 Dept Dermatol West Lake Rd 38 Hangzhou 310009;

    Zhejiang Chinese Med Univ Hangzhou Peoples Hosp 3 Dept Dermatol West Lake Rd 38 Hangzhou 310009;

    Zhejiang Chinese Med Univ Hangzhou Peoples Hosp 3 Dept Dermatol West Lake Rd 38 Hangzhou 310009;

    Zhejiang Chinese Med Univ Hangzhou Peoples Hosp 3 Dept Dermatol West Lake Rd 38 Hangzhou 310009;

    Zhejiang Chinese Med Univ Hangzhou Peoples Hosp 3 Dept Dermatol West Lake Rd 38 Hangzhou 310009;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 免疫性疾病;
  • 关键词

    Hydroxychloroquine; systemic lupus erythematosus; treatment; network pharmacology;

    机译：羟氯喹;Systemic Lupus红斑;治疗;网络药理学;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号